Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy
The purpose of the study is to evaluate the objective tumor response rate of amrubicin when administered as second-line therapy to ED-SCLC patients who have refractory or progressive disease.
Small Cell Lung Cancer
DRUG: Amrubicin
Objective tumor response rate according to RECIST, Until Disease Progression
Duration of overall response, Until Disease Progression|Time to tumor progression, Until Disease Progression|Progression free survival, Until death or disease progression|Overall survival, Until death|Toxicity profile, Until 30 days after final dose|Incidence of cardiomyopathy, Until end of study participation|Incidence of CNS progression, Until disease progression|Pharmacokinetic parameters, Cycle 1 only
The purpose of the study is to evaluate the objective tumor response rate of amrubicin when administered as second-line therapy to ED-SCLC patients who have refractory or progressive disease.